Market capitalization | $102.01m |
Enterprise Value | $162.71m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.10 |
P/S ratio (TTM) P/S ratio | 0.69 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 1.77% |
Revenue (TTM) Revenue | $148.44m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
7 Analysts have issued a Karyopharm Therapeutics, Inc. forecast:
7 Analysts have issued a Karyopharm Therapeutics, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 148 148 |
2%
2%
|
|
Gross Profit | 142 142 |
1%
1%
|
|
EBITDA | -126 -126 |
0%
0%
|
EBIT (Operating Income) EBIT | -126 -126 |
0%
0%
|
Net Profit | -87 -87 |
37%
37%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Karyopharm Therapeutics, Inc. is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Its SINE compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIOTM (selinexor), received accelerated approval from the FDA in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. A Marketing Authorization Application for selinexor is also currently under review by the European Medicines Agency (EMA). In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.
Head office | United States |
CEO | Richard Paulson |
Employees | 325 |
Founded | 2008 |
Website | www.karyopharm.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.